Free Trial

Arrowhead Pharmaceuticals (ARWR) Stock Price, News & Analysis

-0.03 (-0.11%)
(As of 08:37 AM ET)
Today's Range
50-Day Range
52-Week Range
1,257 shs
Average Volume
1.30 million shs
Market Capitalization
$3.49 billion
P/E Ratio
Dividend Yield
Price Target

Arrowhead Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.70 Rating Score
58.5% Upside
$44.56 Price Target
Short Interest
7.17% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
1.32mentions of Arrowhead Pharmaceuticals in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$279,415 Sold Last Quarter
Proj. Earnings Growth
From ($3.04) to ($2.71) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.62 out of 5 stars

Medical Sector

71st out of 912 stocks

Pharmaceutical Preparations Industry

25th out of 434 stocks

ARWR stock logo

About Arrowhead Pharmaceuticals Stock (NASDAQ:ARWR)

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

ARWR Stock Price History

ARWR Stock News Headlines

Does this make you sick?
The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.
Does this make you sick?
The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.
See More Headlines
Receive ARWR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
10 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$240.74 million
Book Value
$2.68 per share


Free Float
Market Cap
$3.49 billion
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Christopher R. Anzalone Ph.D. (Age 55)
    CEO, President & Director
    Comp: $1.6M
  • Mr. Kenneth A. MyszkowskiMr. Kenneth A. Myszkowski (Age 58)
    Chief Financial Officer
    Comp: $834.34k
  • Mr. Patrick O'Brien J.D. (Age 60)
    PharmD, COO, General Counsel & Secretary
    Comp: $835.14k
  • Dr. James C. Hamilton M.D. (Age 46)
    MBA, Chief of Discovery & Translational Medicine
    Comp: $762.14k
  • Dr. Mark M. Davis Ph.D.
    Founder and Founder & Director of Insert Therapeutics Inc & Calando
  • Dr. Vincent Anzalone CFA
    Head of Investor Relations & VP
  • Mr. Howard Lovy
    Director of Communications
  • Dr. Bruce D. Given M.D. (Age 70)
    Chief Medical Scientist
    Comp: $486.31k
  • Dr. Mark Seefeld (Age 70)
    Head of Toxicology & VP
  • Ms. Tracie  OliverMs. Tracie Oliver (Age 62)
    Chief Commercial Officer
    Comp: $449.58k

ARWR Stock Analysis - Frequently Asked Questions

How have ARWR shares performed this year?

Arrowhead Pharmaceuticals' stock was trading at $30.60 at the beginning of the year. Since then, ARWR shares have decreased by 8.1% and is now trading at $28.11.
View the best growth stocks for 2024 here

How were Arrowhead Pharmaceuticals' earnings last quarter?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) posted its earnings results on Thursday, May, 9th. The biotechnology company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.06) by $0.96. The company's quarterly revenue was down 100.0% compared to the same quarter last year.

Who are Arrowhead Pharmaceuticals' major shareholders?

Top institutional investors of Arrowhead Pharmaceuticals include CWM LLC (0.06%) and SG Americas Securities LLC (0.01%). Insiders that own company stock include Christopher Richard Anzalone, Patrick O'brien, Kenneth Allen Myszkowski, James C Hamilton, Martin Javier San, Douglas B Given, Tracie Oliver, Hongbo Lu, Victoria Vakiener, William D Waddill and Adeoye Y Olukotun.
View institutional ownership trends

How do I buy shares of Arrowhead Pharmaceuticals?

Shares of ARWR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Arrowhead Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Alliance Resource Partners (ARLP) and Bank of America (BAC).

This page (NASDAQ:ARWR) was last updated on 7/15/2024 by Staff

From Our Partners